1. Home
  2. THAR

as 04-02-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Founded: 2017 Country:
United States
United States
Employees: N/A City: BRIDGEWATER
Market Cap: 4.0M IPO Year: 2022
Target Price: $17.00 AVG Volume (30 days): 135.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -9.41 EPS Growth: N/A
52 Week Low/High: $1.20 - $7.13 Next Earning Date: 05-08-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

THAR Daily Stock ML Predictions

Share on Social Networks: